The Syneos Health Podcast cover art

All Episodes

The Syneos Health Podcast — 197 episodes

#
Title
1

Everybody Wins: Elevating the Patient Voice

2

Introducing: Early Signals

3

Site Realities Series | Navigating Complexity: Communication, Escalation Paths and Site Partnership at Scale

4

Site Realities Series | Building Trust at the Site Level: The CRA as Ambassador and Partner

5

Introducing: Conversations on Commercialization

6

Site Realities Series | From Monitor to Strategic Partner: The Evolution of the CRA Role

7

Site Realities Series | Inside the Site Experience: Challenges, Tradeoffs and Opportunities

8

Conversations on Commercialization: Navigating Dermatology’s New Access Landscape with Paul Rittman of Almirall US

9

Functionally Speaking Series: Regulatory Intelligence, Medical Writing and the AI Inflection Point

10

Functionally Speaking Series: Reimagining Site Experience: CRAs, AI and the Future of Functional Models

11

Functionally Speaking Series: Modernizing Safety and Pharmacovigilance, The Human in the Loop

12

Functionally Speaking Series: Clinical Operations for Large Pharma, Navigating Model Evolution With Agility

13

Functionally Speaking Series: FSP for SMID Sponsors, Navigating Complexity with Flexibility and Trust

14

2025 CNS Summit Series: Scaling Psychedelic Medicines Responsibly, A Conversation with Dr. Dan Karlin, CSO, MindMed

15

2025 CNS Summit Series: Revolutionizing Clinical Trials with Virtual Patients, A Conversation with Anzar Abbas, CEO, Brooklyn Health

16

2025 CNS Summit Series: Rewriting the Rules of Neurodegeneration, A Conversation with Arvinas CSO Angela Cacace, PhD

17

CNS Summit Series: Balanced Disruption in Neurology, A Conversation with Merz Therapeutics CEO Stefan König

18

Conversations on Commercialization: Changing the Name Game with Addison Whitney’s Ari™

19

CNS Summit Series: Can Psychedelics Reshape Psychiatry? A Conversation with Kabir Nath, CEO, Compass Pathways

20

Conversations on Commercialization: GLP-1 Gold Rush — Who’s Really Winning in the New Obesity Market?

21

Conversations on Commercialization: DTP, AI and the Future of Pharma Access

22

Conversations on Commercialization: The New Rules of HCP Engagement

23

2025 Health Trends | Getting Real About Omnichannel: A View from the Leading Edge

24

Asembia AXS25 Series: Redefining Access for Enhanced Retail Therapies, with Cheryl Allen of Curatio Advisors

25

Asembia AXS25 Series: Reimagining Patient Support: Scaling Access, Affordability and AI Integration with Kelly Carter of Amgen

26

Asembia AXS25 Series: Redefining Market Access: Patient Support, Technology and Pharma Strategy with Rob Truckenmiller of PharmaCord

27

Asembia AXS25 Series: Holistic Patient Support with Tiara Green of Accessia Health

28

Asembia AXS25 Series: Modernizing Patient Services: AI, Hybrid Models and Innovation Strategy with Greg Morris of CareMetx

29

Project Optimus Series: Clinical Pharmacology and Project Optimus

30

2025 Health Trends | Strategy, Agility and Innovation in Launch Excellence

31

2025 Health Trends | AI as an R&D Investment

32

Asembia AXS25 Series: Navigating Modern Market Access

33

Project Optimus Series: The Role of Biostatistics

34

Project Optimus Series: Operationalizing Dose Optimization

35

Opportunities Abound for PDTs, with Click Therapeutics

36

Unlocking the Black Box of Psychiatric Clinical Research, with Dr. Rishi Kakar of Segal Trials

37

Project Optimus Series: The Regulatory Implications of Project Optimus

38

CNS Summit Series: Pioneering Patient Advocacy, with Ryan Brooks from CenExel

39

CNS Summit Series: Future-Proofing Clinical Trials

40

CNS Summit Series: Pioneering Psychiatry - Behind the Breakthrough KarXT with Dr. Stephen Brannan

41

CNS Summit Series: Decoding Biology to Radically Change the Lives of Patients, with Dr. Najat Khan of Recursion Pharma

42

CNS Summit Series: Schizophrenia, Clinical Trials and Hope, with Dr. David Walling of Cenexel CNS

43

CNS Summit Series: The Future of Immunology and Personalized Health,with Jane Metcalfe of The Human Immunome Project

44

CNS Summit Series: Psychedelics and Beyond, with Kevin Craig of atai Life Sciences

45

CNS Summit Series: Redefining Psychiatry with Science and Compassion, with Dr. David Brown of Community Clinical Research

46

CNS Summit Series: Patient-Centric Innovation at Scale, with Cristina Duran of Evinova

47

CNS Summit Series: Celebrating 15 Years of Innovation with Dr. Amir Kalali of CNS Summit

48

Project Optimus Series: Navigating the Realities of Project Optimus

49

Psychedelics 3.0: Challenges and Opportunities in an Evolving Field

50

A Site-Specific Approach to Optimizing Diversity in Oncology Trials

51

Circulating Tumor DNA: Transforming Oncology Clinical Trials

52

Cashing in on the Currency of Information

53

Decoding Gen AI’s Potential to Drive More Effective Clinical Trials

54

Connecting the Global Dots on Carbon Footprint in Biopharma

55

Can AI Help Get the Right Patients Into Alzheimer's Clinical Trials?

56

Unpacking the Role of Adjuvant Therapies in Breast Cancer

57

Site and Study Execution for Ophthalmology Trials

58

The Case for Genetic Medicines

59

Jeff Stewart Says Goodbye

60

Patient Assistance: The Best Deal in Pharma

61

Real Talk About the Inflation Reduction Act

62

Turbo-Charging Clinical Trials

63

Investing for Commercial Success as an Emerging Company

64

Ophthalmology Clinical Trials: Low Vision and AMD Awareness Month

65

FDA Rules for Radio & TV Advertising

66

2024 Health Trends: Managing the Healthcare Revolution

67

World Mental Health Day: The State of Mental Health Clinical Development

68

Radiosensitizers in Head and Neck Cancer

69

Market Access for Weight Loss Drugs

70

Training MSLs in the Metaverse

71

Biopharma and the Emergency Department

72

Biotech Value Creation

73

2023 Health Trends: Improved Sophistication in Retention

74

Digital Therapeutic Development and Approval

75

Digital Therapeutic Commercialization

76

Cancer: The Patient Perspective

77

2023 Health Trends: The Data Effect

78

2023 Health Trends: A New Field for the Field Force

79

2023 Health Trends: Digital Transformation: Start, Stall, Restart

80

Gene Therapy for Hemophilia

81

The Inflation Reduction Act

82

2023 Health Trends: AI: Finally Fit for Purpose

83

2023 Health Trends: AgeTech with Musician, Actor and Patient Advocate James Ian

84

Reg Ops Edition: Attracting and Retaining Talent

85

Life Sciences Dealmaking: Dealmakers' Intentions 2023

86

2023 Health Trends: Personally, Purposefully Building What’s Next

87

Real World Evidence and Rare Diseases, Part 3: The Value of Registries

88

Decentralized Clinical Trials: Implications for Biotech

89

Full-Service Commercial

90

MAPS Edition: Value Demonstration - A View From the Top

91

MAPS Edition: Bringing Medical Affairs Into the C-Suite

92

Opportunities and Challenges in Cell and Gene Therapy

93

MAPS Edition: Recruiting for the New Profile of Medical Affairs

94

MAPS Edition: Stakeholder Engagement in a Data-Driven Environment

95

MAPS Edition: Measuring the Immeasurable: Value and Impact of Medical Affairs

96

MAPS Edition: Be Bold - Preparing Medical Affairs for 2030 and Beyond

97

Training the Next Generation of Pharma

98

Getting Access

99

Epilepsy, the Central Nervous System and Rare Disease

100

The Placebo Effect

101

Mental Health in Rare Disease

102

Navigating the Rare Disease Landscape

103

Business Continuity Through Strategic Outsourcing

104

The Virtual Sales Organization

105

Thirty Years of Physician Answers

106

Syneos Short: Talking to Our Families About COVID-19 Vaccines

107

2021 HEALTH TRENDS EDITION: Leading Change in China

108

2021 HEALTH TRENDS EDITION: Field Force of the Future

109

2021 HEALTH TRENDS EDITION: Omnichannel Experience

110

Storytelling in Pharma

111

2021 HEALTH TRENDS EDITION: Remote Care in 2021 and Beyond

112

Virtual Pharma

113

Pharmacovigilance in the COVID-19 Era and Beyond

114

Lifecycle Management

115

Source Document Review in the Modern World

116

Learning Agility in Medical Affairs

117

Trade and Distribution in Pharma: It's Complicated

118

Peter Kolchinsky and Investing in Biopharma

119

Peter Kolchinsky and The Great American Drug Deal

120

Real World Evidence and Rare Diseases

121

Global Pharma

122

APAC EDITION: Clinical Development in Japan

123

Learning Agility

124

China vs. Cancer

125

Rapid Early Phase Clinical Trials

126

Payer Power, Part 3

127

CORONAVIRUS SPECIAL EDITION, Episode 12: COVID-19 and Children

128

CORONAVIRUS SPECIAL EDITION, Episode 11: Rare Disease Clinical Trials and COVID-19

129

NEWYORKBIO BIOPHARMA INNOVATORS SERIES: Yelp Ratings for Clinical Trials

130

NEWYORKBIO BIOPHARMA INNOVATORS SERIES: Taming the Healthcare Data Explosion

131

NEWYORKBIO BIOPHARMA INNOVATORS SERIES: Real World Data for Clinical Innovation

132

CORONAVIRUS SPECIAL EDITION, Episode 10: Ventilating the COVID-19 Patient

133

CORONAVIRUS SPECIAL EDITION, Episode 9: Telemedicine in the Age of COVID-19

134

CORONAVIRUS SPECIAL EDITION, Episode 8: Payers and COVID-19

135

CORONAVIRUS SPECIAL EDITION, Episode 7: Continuity in Clinical Trials

136

CORONAVIRUS SPECIAL EDITION, Episode 6: The Leader's Experience

137

CORONAVIRUS SPECIAL EDITION, Episode 5: Surviving the Ventilator Shortage

138

CORONAVIRUS SPECIAL EDITION, Episode 4: Clinical Trials Through Pandemics

139

CORONAVIRUS SPECIAL EDITION, Episode 3: Virtual Clinical Trials

140

CORONAVIRUS SPECIAL EDITION, Episode 2: The Clinical Experience

141

CORONAVIRUS SPECIAL EDITION, Episode 1: The Personal Experience

142

Recruiting Patients for Clinical Trials

143

Medical Affairs Series, Part Six: Commercial Plus Medical Affairs

144

2020 Health Trends: Box Store Healthcare

145

Denials, Delays and Deep Discounts in Pharmaceutical Launch

146

Medical Affairs Series, Part Five: Medical Affairs in the Early Stage

147

Real World Evidence and Rare Diseases

148

The Digital Therapeutics Alliance: A European Perspective

149

Medical Affairs Series, Part Four: Medical Affairs in the Field

150

Medical Affairs Series, Part Three: Moving to the Left

151

Advocacy Archetypes

152

Medical Affairs Series, Part Two - Measuring the Unmeasurable: Medical Affairs Metrics

153

Why We Resist

154

Medical Affairs Series, Part One: A Foundation for Medical Affairs

155

A Regulatory Roadmap for Real World Evidence

156

Talented Teams

157

Digital Therapeutics

158

Talking About PIE

159

MOAs in ONC: The Latest and Greatest in the Oncology Pipeline

160

Episode 037: Psychology in Clinical Trials

161

Episode 036: Commercialization for Emerging Companies

162

Episode 035: How Translational Science Can Solve Pharma's Productivity Puzzle

163

Episode 034: Can the Gut Microbiome Revolutionize Medical Care?

164

APAC Edition: Medical Affairs in China

165

Episode 033: From DTC to DT"Me" - The Future of Communications in Pharmaceuticals

166

Episode 032: Navigating the New EU Medical Device Regulations

167

APAC Edition: Acceleration in Asia

168

Episode 031: Real World Evidence in Europe

169

Episode 030: Land of Opportunity: R&D in Asia Pacific

170

Episode 029: Commercial Models of the (Very Near) Future

171

Episode 028: World Cancer Day

172

Episode 027: Caregivers

173

Episode 026: The Health Trend Ten - Clinical Perspective

174

Episode 025: The Health Trend Ten - Commercial Perspective

175

Episode 024: Content that Clicks

176

Episode 023: The Clinical Trial Marathon, at a Sprint

177

Episode 022: Spending for Launch Success

178

Episode 021: The Sales Force Training (R)evolution

179

Episode 020: A Syneos Health Short - 21st Century Cures

180

Episode 019: A Decade of Dealmakers' Intentions

181

Episode 018: Partnering with a CRO

182

Episode 016: Payer Power, Part 2

183

Episode 015: ICER - Friend or Foe?

184

Episode 014: MA-"Squared": Medical Affairs Meets Market Access

185

Episode 009: Rare Diseases

186

Episode 013: Artificial Intelligence for Authentic Engagement

187

Episode 012: Medical Affairs from Zero

188

Episode 011: Naming, Part 2 - The Drug

189

Episode 010: Naming, Part 1 - The Pharma Company

190

Episode 008: Social Centricity

191

Episode 007: Medicine in 140 Characters: Digital KOLs

192

Episode 006: Crossing the Finish Line: Factors Driving Patient Adherence to Drug Therapy

193

Episode 005: The Room Where it Happens: Dealmakers' Intentions 2017

194

Episode 004: Innovation in Pharma Communications

195

Episode 003: Payer Power

196

Episode 002: The Impact of AHCA on Pharma

197

Episode 001: The Real-World Evidence Revolution